person

Stephen R. Marder, MD

Stephen Marder, MDStephen R Marder, MD
ORCID 0000-0003-0288-309X
as of 2026-07-01
at a glance
Roles: Principal Investigator, Study Chair, Author
KOL signal score 14
5 publications · 1 high-value
Cross-drug reach: 2 competitor drugs
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
University of California, Los Angeles
Roles
Principal Investigator, Study Chair, Author
KOL signal
14
Publications
5 (1 high-value)
Trial investigator
yes

Publishes on

2 drugs

Trials led

5

Publications & congress

5
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
Schizophrenia research · 2024 · high-value
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction.
Schizophrenia bulletin open · 2026
A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 1: Perceived Impact on Symptoms.
Schizophrenia bulletin open · 2026
Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia.
Schizophrenia research · 2026
Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy.
Schizophrenia bulletin open · 2022

Facts & assertions

0 sourced
No assertions recorded for this entity.